

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7358817

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	MERGER
<b>EFFECTIVE DATE:</b>	08/27/2021
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
GRACE THERAPEUTICS INC.	08/26/2021
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ACASTI PHARMA U.S., INC.
<b>Street Address:</b>	675 US HIGHWAY 1
<b>City:</b>	NEW BRUNSWICK
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	08902
<b>PROPERTY NUMBERS Total: 7</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	17011345
Patent Number:	10799486
Patent Number:	10765671
Patent Number:	10092553
Patent Number:	10092557
Application Number:	63342204
Patent Number:	11291672
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(212)736-2427
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2127361940
<b>Email:</b>	ysukhorska@ddkpatent.com, ddk@ddkpatent.com
<b>Correspondent Name:</b>	DAVIDSON, DAVIDSON & KAPPEL, LLC
<b>Address Line 1:</b>	589 EIGHTH AVENUE
<b>Address Line 2:</b>	22ND FLOOR
<b>Address Line 4:</b>	NEW YORK, NEW YORK 10018
<b>ATTORNEY DOCKET NUMBER:</b>	1007.1000
<b>NAME OF SUBMITTER:</b>	OLEG IOSELEVICH
<b>SIGNATURE:</b>	/Oleg Ioselevich/

PATENT

<b>DATE SIGNED:</b>	06/01/2022
---------------------	------------

**Total Attachments: 5**

source=1007-Certificate-of-Merger-Acasti-Pharma#page1.tif

source=1007-Certificate-of-Merger-Acasti-Pharma#page2.tif

source=1007-Certificate-of-Merger-Acasti-Pharma#page3.tif

source=1007-Certificate-of-Merger-Acasti-Pharma#page4.tif

source=1007-Certificate-of-Merger-Acasti-Pharma#page5.tif

# Delaware

The First State

Page 1

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"ACASTI PHARMA U.S., INC.", A DELAWARE CORPORATION,  
WITH AND INTO "GRACE THERAPEUTICS INC." UNDER THE NAME OF  
"ACASTI PHARMA U.S., INC.", A CORPORATION ORGANIZED AND EXISTING  
UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED  
IN THIS OFFICE ON THE TWENTY-SEVENTH DAY OF AUGUST, A.D. 2021,  
AT 8 O`CLOCK A.M.



  
Jeffrey W. Bullock, Secretary of State

6842081 8100M  
SR# 20213096461

You may verify this certificate online at [corp.delaware.gov/authver.shtml](http://corp.delaware.gov/authver.shtml)

Authentication: 204021336  
Date: 08-27-21

**PATENT**  
**REEL: 060065 FRAME: 0062**

**STATE OF DELAWARE**  
**CERTIFICATE OF MERGER**  
**MERGING**

**ACASTI PHARMA U.S., INC.**  
**(A DELAWARE CORPORATION)**

**WITH AND INTO**

**GRACE THERAPEUTICS INC.**  
**(A DELAWARE CORPORATION)**

Pursuant to Title 8, Section 251(c) of the Delaware General Corporation Law, as amended, the undersigned corporation executed the following Certificate of Merger (this "Certificate of Merger"):

**FIRST:** The name of the surviving corporation is Grace Therapeutics Inc., a Delaware corporation, and the name of the corporation being merged with and into the surviving corporation is Acasti Pharma U.S., Inc., a Delaware corporation (the "Non-Survivor").

**SECOND:** The Agreement and Plan of Merger has been approved, adopted, certified, executed and acknowledged by the surviving corporation and the Non-Survivor.

**THIRD:** The name of the surviving corporation is Grace Therapeutics Inc. Upon the filing of this Certificate of Merger with the Secretary of State of the State of Delaware, the name of the surviving corporation shall be Acasti Pharma U.S., Inc.

**FOURTH:** The merger is to become effective as of the date and time this Certificate of Merger is filed with the Secretary of State of the State of Delaware (the "Effective Time").

**FIFTH:** Upon the effectiveness of the merger, the Certificate of Incorporation of the surviving corporation shall be amended and restated to read in its entirety as set forth in **Exhibit A** attached hereto, and, as amended and restated, shall constitute the Amended and Restated Certificate of Incorporation of the surviving corporation until thereafter amended in accordance with its terms and applicable law.

**SIXTH:** The Agreement and Plan of Merger is on file at 3009 boul. De la Concorde E., Suite 102, Laval, Québec, Canada H7E 2B5, the place of business of the surviving corporation.

**SEVENTH:** A copy of the Agreement and Plan of Merger will be furnished by the surviving corporation on request, without cost, to any stockholder of the surviving corporation or the Non-Survivor.

**[SIGNATURE PAGE TO FOLLOW]**

IN WITNESS WHEREOF, the surviving corporation has caused this Certificate of Merger to be signed by an authorized officer, this 26th day of August, 2021.

**GRACE THERAPEUTICS INC.,** a  
Delaware corporation

DocuSigned by:  
*George Kottayil*  
FCEAAF82A7A2487...

By: \_\_\_\_\_  
Name: S. George Kottayil  
Title: Chief Executive Officer

**EXHIBIT A**

**AMENDED AND RESTATED  
CERTIFICATE OF INCORPORATION OF  
SURVIVING CORPORATION**

(See attached.)

AMENDED AND RESTATED  
CERTIFICATE OF INCORPORATION  
OF  
ACASTI PHARMA U.S., INC.

**ARTICLE I:** The name of the corporation is Acasti Pharma U.S., Inc. (the “Corporation”).

**ARTICLE II:** The address of the registered office of the Corporation in the State of Delaware is located at 251 Little Falls Drive, Wilmington, Delaware, 19808 in the County of New Castle. The name of the registered agent of the Corporation at such address is Corporation Service Company.

**ARTICLE III:** The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware (the “DGCL”).

**ARTICLE IV:** The total number of shares of stock which the Corporation shall have authority to issue shall be 30,000,000 shares of common stock, par value US\$0.01 per share.

**ARTICLE V:** In furtherance and not in limitation of the powers conferred by statute, the board of directors of the Corporation is expressly authorized to adopt, amend or repeal the bylaws of the Corporation.

**ARTICLE VI:** A director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director except for liability (i) for any breach of the director's duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL or (iv) for any transaction from which the director derived an improper personal benefit.

**ARTICLE VII:** Unless and except to the extent that the bylaws of the Corporation shall so require, the election of directors of the Corporation need not be by written ballot.

\* \* \*